Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / NVSEF - The Commercial Potential Of Crispr In Light Of Patent Challenges

NVSEF - The Commercial Potential Of Crispr In Light Of Patent Challenges

Novartis Ag Basel Akt
  • CRSP needs to make tough decisions regarding the loss of critical CRISPR patents in the US.
  • CRSP differentiates itself by creating allogeneic CAR-T therapy allowing mass production, off-shelf availability, and potentially low production cost.
  • The company is the wealthiest CRISPR biotech, thanks to lucrative partnerships.

For further details see:

The Commercial Potential Of Crispr In Light Of Patent Challenges
Stock Information
Company Name: Novartis Ag Basel Akt
Stock Symbol: NVSEF
Market: OTC
Website: novartis.com
Menu
NVSEF NVSEF Quote NVSEF Short NVSEF News NVSEF Articles NVSEF Message Board
Get NVSEF Alerts

News, Short Squeeze, Breakout and More Instantly...